TAPERANK
Open the app
MOVER · THU OCT 15 2026

Why VBIO rose 25.5% on Oct 15 2026: feasibility evaluation

VBIO+25.5%on Thu Oct 15 2026

Valion Bio, Inc. Common Stock was up 25.5% on the day at $1.82, ranked #2 on 472× its usual five-minute volume, when TapeRank recorded this spike at 08:03 ET during the pre-market session.

THE DAY ON THE LIST · 1 EVENT

  1. 08:03 ET
    MOVER · PRE-MARKET

    $1.82 · ▲ 25.5% ON THE DAY · 472× 5M RVOL · RANK #2

    JUSTIFIEDCONFIDENCE4/5

    VBIO is up 10.3% pre-market with accelerating volume after announcing completion of an initial feasibility evaluation of LarmorBio’s BioScan-NMR platform. The news is an early technical milestone rather than a quantified commercial deal, but a roughly 10% move is proportionate for a low-priced clinical-stage stock on this update.

    WHYUp 10.3% on an initial feasibility milestone with no disclosed financial terms is a moderate move, not materially larger than the news supports.
    ANALYZED 08:01 ET · 2 MIN AGO · OPENAI/GPT-5.6-LUNA
    THE ROW AND SESSION LEVELS AT 08:03 ET
    LAST1.82
    DAY▲ 25.5%
    5 MIN▲ 18.95%
    5M RVOL472×
    5M $VOL$1.3M
    FLOAT*22.2M
    RANK#2
    SESSIONPRE-MARKET
    VWAP1.66
    HOD1.82
    LOD1.45
    OR HIGH—
    OR LOW—
    PREV CLOSE1.45
    PM HIGH1.82
    PM LOW1.45
    GAP▲ 17.46% (indicated)

    * FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE

    — MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO

THE SESSION

  • 09:30 ETOpened at $1.11, -23.4% on the previous close of $1.45
  • 09:30 ETRegular-session low, $1.11
  • 10:50 ETRegular-session high, $1.33
  • 15:59 ETLast trade of the regular session, $1.20, -17.2% on the previous close of $1.45
  • Volume: 1.7M shares in regular hours, 11.7M before the open

VBIO opened at $1.11, matching the session low and 23.4% below the previous close, after TapeRank had recorded it at $1.82 before the open. TapeRank read the premarket move as justified by the announced completion of an initial feasibility evaluation of LarmorBio’s BioScan-NMR platform, an early technical milestone with no disclosed financial terms. The stock climbed to $1.33 at 10:50 ET before reversing to finish the regular session at $1.20, still 17.2% below the previous close; no halts were recorded.

WRITTEN THU OCT 15 2026 18:53 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE

FILINGS AND NEWS · 24H BEFORE THE MOVE

On the tape right now

WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY

01
ECGSURGING 0:05
79.71
▼ 29.3%
▼ 1.41%
41.0×
FAD
$6.2M
51.1M*
STRETCHED
02
CAVASURGING 0:00
64.78
▲ 7.4%
▲ 1.30%
9.3×
ORBHODVWH
$11.6M
116.8M*
UNEXPLAINED
03
URGNSURGING 0:00
29.16
▼ 15.2%
▼ 1.29%
15.6×
FAD
$1.4M
48.9M*
JUSTIFIED
04
MPTISURGING 0:00
64.15
▼ 1.5%
▲ 0.96%
23.8×
VWH
$637K
4.3M*
UNEXPLAINED
05
LSPDSURGING 0:00
11.52
▲ 4.9%
▼ 1.24%
16.5×
ORB
$426K
133.3M*
UNEXPLAINED
06
CRCTSURGING 0:00
8.90
▲ 49.2%
▼ 0.72%
15.1×
GAPORBVWHEXT
$395K
54.7M*
STRETCHED
07
BROSSURGING 0:00
43.97
▲ 0.9%
▼ 0.91%
4.0×
FAD
$4.3M
137.9M*
UNEXPLAINED
08
LMRICOOLING 1:35
12.85
▲ 14.5%
▲ 1.06%
132×
ORBHODVWH
$1.7M
—
UNEXPLAINED
Open the full list